Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children

The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the two. Though several African countries continue to use quinine as the se...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-01, Vol.8 (1), p.e53772
Main Authors: Yeka, Adoke, Tibenderana, James, Achan, Jane, D'Alessandro, Umberto, Talisuna, Ambrose O
Format: Article
Language:English
Subjects:
Antimalarials - adverse effects
Antimalarials - therapeutic use
Artemether
Artemisinin
Artemisinins - adverse effects
Artemisinins - therapeutic use
Biology
Child, Preschool
Children
Clinical trials
Dihydroartemisinin
Disease transmission
Drug therapy
Effectiveness
Ethanolamines - adverse effects
Ethanolamines - therapeutic use
Fluorenes - adverse effects
Fluorenes - therapeutic use
Health risks
Humans
Infant
Infection
Infections
Malaria
Malaria, Falciparum - drug therapy
Male
Medical law
Medicine
Patients
Plasmodium falciparum
Quinine
Quinine - adverse effects
Quinine - therapeutic use
Quinolines - adverse effects
Quinolines - therapeutic use
Recurrent infection
Safety
Statistical analysis
Surveillance
Therapy
Treatment Outcome
Uganda
Vector-borne diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3
cites cdi_FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3
container_end_page
container_issue 1
container_start_page e53772
container_title PloS one
container_volume 8
creator Yeka, Adoke
Tibenderana, James
Achan, Jane
D'Alessandro, Umberto
Talisuna, Ambrose O
description The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the two. Though several African countries continue to use quinine as the second line treatment for patients with recurrent infections, there is little information on its efficacy when used for rescue therapy. Moreover, such practice goes against the World Health Organisation (WHO) recommendation to use combination therapy for uncomplicated malaria. We conducted a nested, randomized, open label, three-arm clinical trial of rescue therapy in children 6-59 months old with recurrent malaria infection during 28 days post treatment with artemisinin combination treatment (ACT). Patients were randomly assigned to receive either quinine, artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHAPQ), and actively followed up for 28 days. Among 220 patients enrolled, 217 (98·6%) were assigned an efficacy outcome and 218 (99·1%) were assessed for safety. The risk of recurrent infection was significantly higher in patients treated with quinine (70%, 74/110, HR = 3·9; 95% CI: 2·4-6·7, p
doi_str_mv 10.1371/journal.pone.0053772
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1327798801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478167149</galeid><doaj_id>oai_doaj_org_article_d95bc171a4b74a5d97cf4b9ddbb8a526</doaj_id><sourcerecordid>A478167149</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3</originalsourceid><addsrcrecordid>eNqNk9-K1DAUxoso7rr6BqIBQRDs2DRp094Iy7LqwMKCut6G0_yZydAms0kqzmP4xmZ2ussUFKQXbZPf953kS06WvcTFAhOGP2zc6C30i62zalEUFWGsfJSd4paUeV0W5PHR90n2LITNHmrq-ml2UhJCW0bxafb7UmsjQOyQ0-h2NNZY9R6Bj2pQca183o-D0mCjTxMIrETSrHfSuzvEhL0g35qt8rBXJyQgr4IYFYpeQRyUjUg7j0Yr3LDtU62oJBqgB28AGYtuVskVLBJr00uv7PPsiYY-qBfT-yy7-XT5_eJLfnX9eXlxfpULVjUxL6EqNU77wbRmmhDBdKMVCEoLQdqaCQ11ywSwAjctw1KX6QegLSWtqWQdOcteH3y3vQt8SjNwTErG2qYpcCKWB0I62PCtNwP4HXdg-N2A8yueUjCiV1y2VScww0A7RqGSqbKmXStl1zVpoXXy-jhVG7tBSZFi8dDPTOcz1qz5yv3kpKpw2k4yeDMZeHc7qhD_seSJWkFalbHaJTORzknwc8oaXDNM20Qt_kKlR6YjFek-aZPGZ4J3M0FiovoVVzCGwJffvv4_e_1jzr49YtcK-rgOrh-jcTbMQXoAhXcheKUfksMF37fDfRp83w58aocke3Wc-oPo_v6TP46gCcM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1327798801</pqid></control><display><type>article</type><title>Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Yeka, Adoke ; Tibenderana, James ; Achan, Jane ; D'Alessandro, Umberto ; Talisuna, Ambrose O</creator><contributor>Gosling, Roly D.</contributor><creatorcontrib>Yeka, Adoke ; Tibenderana, James ; Achan, Jane ; D'Alessandro, Umberto ; Talisuna, Ambrose O ; Gosling, Roly D.</creatorcontrib><description>The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the two. Though several African countries continue to use quinine as the second line treatment for patients with recurrent infections, there is little information on its efficacy when used for rescue therapy. Moreover, such practice goes against the World Health Organisation (WHO) recommendation to use combination therapy for uncomplicated malaria. We conducted a nested, randomized, open label, three-arm clinical trial of rescue therapy in children 6-59 months old with recurrent malaria infection during 28 days post treatment with artemisinin combination treatment (ACT). Patients were randomly assigned to receive either quinine, artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHAPQ), and actively followed up for 28 days. Among 220 patients enrolled, 217 (98·6%) were assigned an efficacy outcome and 218 (99·1%) were assessed for safety. The risk of recurrent infection was significantly higher in patients treated with quinine (70%, 74/110, HR = 3·9; 95% CI: 2·4-6·7, p&lt;0·0001) and AL (60%, 21/35, HR = 3·3; 95% CI: 1·8-6·3, p&lt;0·0002), compared to DHAPQ (25%, 18/72). Recrudescence tended to be lower in the DHAPQ (1%, 1/72) than in the quinine (7%, 8/110) or AL (6%, 2/35) group, though it was not statistically significant. No serious adverse events were reported. Recurrent infections observed after the administration of an ACT can be successfully treated with an alternative ACT rather than with quinine. Current Controlled Trials ISRCTN99046537.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0053772</identifier><identifier>PMID: 23349741</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Antimalarials - adverse effects ; Antimalarials - therapeutic use ; Artemether ; Artemisinin ; Artemisinins - adverse effects ; Artemisinins - therapeutic use ; Biology ; Child, Preschool ; Children ; Clinical trials ; Dihydroartemisinin ; Disease transmission ; Drug therapy ; Effectiveness ; Ethanolamines - adverse effects ; Ethanolamines - therapeutic use ; Fluorenes - adverse effects ; Fluorenes - therapeutic use ; Health risks ; Humans ; Infant ; Infection ; Infections ; Malaria ; Malaria, Falciparum - drug therapy ; Male ; Medical law ; Medicine ; Patients ; Plasmodium falciparum ; Quinine ; Quinine - adverse effects ; Quinine - therapeutic use ; Quinolines - adverse effects ; Quinolines - therapeutic use ; Recurrent infection ; Safety ; Statistical analysis ; Surveillance ; Therapy ; Treatment Outcome ; Uganda ; Vector-borne diseases</subject><ispartof>PloS one, 2013-01, Vol.8 (1), p.e53772</ispartof><rights>COPYRIGHT 2013 Public Library of Science</rights><rights>2013 Yeka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Yeka et al 2013 Yeka et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3</citedby><cites>FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1327798801/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1327798801?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23349741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Gosling, Roly D.</contributor><creatorcontrib>Yeka, Adoke</creatorcontrib><creatorcontrib>Tibenderana, James</creatorcontrib><creatorcontrib>Achan, Jane</creatorcontrib><creatorcontrib>D'Alessandro, Umberto</creatorcontrib><creatorcontrib>Talisuna, Ambrose O</creatorcontrib><title>Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the two. Though several African countries continue to use quinine as the second line treatment for patients with recurrent infections, there is little information on its efficacy when used for rescue therapy. Moreover, such practice goes against the World Health Organisation (WHO) recommendation to use combination therapy for uncomplicated malaria. We conducted a nested, randomized, open label, three-arm clinical trial of rescue therapy in children 6-59 months old with recurrent malaria infection during 28 days post treatment with artemisinin combination treatment (ACT). Patients were randomly assigned to receive either quinine, artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHAPQ), and actively followed up for 28 days. Among 220 patients enrolled, 217 (98·6%) were assigned an efficacy outcome and 218 (99·1%) were assessed for safety. The risk of recurrent infection was significantly higher in patients treated with quinine (70%, 74/110, HR = 3·9; 95% CI: 2·4-6·7, p&lt;0·0001) and AL (60%, 21/35, HR = 3·3; 95% CI: 1·8-6·3, p&lt;0·0002), compared to DHAPQ (25%, 18/72). Recrudescence tended to be lower in the DHAPQ (1%, 1/72) than in the quinine (7%, 8/110) or AL (6%, 2/35) group, though it was not statistically significant. No serious adverse events were reported. Recurrent infections observed after the administration of an ACT can be successfully treated with an alternative ACT rather than with quinine. Current Controlled Trials ISRCTN99046537.</description><subject>Antimalarials - adverse effects</subject><subject>Antimalarials - therapeutic use</subject><subject>Artemether</subject><subject>Artemisinin</subject><subject>Artemisinins - adverse effects</subject><subject>Artemisinins - therapeutic use</subject><subject>Biology</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Dihydroartemisinin</subject><subject>Disease transmission</subject><subject>Drug therapy</subject><subject>Effectiveness</subject><subject>Ethanolamines - adverse effects</subject><subject>Ethanolamines - therapeutic use</subject><subject>Fluorenes - adverse effects</subject><subject>Fluorenes - therapeutic use</subject><subject>Health risks</subject><subject>Humans</subject><subject>Infant</subject><subject>Infection</subject><subject>Infections</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Male</subject><subject>Medical law</subject><subject>Medicine</subject><subject>Patients</subject><subject>Plasmodium falciparum</subject><subject>Quinine</subject><subject>Quinine - adverse effects</subject><subject>Quinine - therapeutic use</subject><subject>Quinolines - adverse effects</subject><subject>Quinolines - therapeutic use</subject><subject>Recurrent infection</subject><subject>Safety</subject><subject>Statistical analysis</subject><subject>Surveillance</subject><subject>Therapy</subject><subject>Treatment Outcome</subject><subject>Uganda</subject><subject>Vector-borne diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9-K1DAUxoso7rr6BqIBQRDs2DRp094Iy7LqwMKCut6G0_yZydAms0kqzmP4xmZ2ussUFKQXbZPf953kS06WvcTFAhOGP2zc6C30i62zalEUFWGsfJSd4paUeV0W5PHR90n2LITNHmrq-ml2UhJCW0bxafb7UmsjQOyQ0-h2NNZY9R6Bj2pQca183o-D0mCjTxMIrETSrHfSuzvEhL0g35qt8rBXJyQgr4IYFYpeQRyUjUg7j0Yr3LDtU62oJBqgB28AGYtuVskVLBJr00uv7PPsiYY-qBfT-yy7-XT5_eJLfnX9eXlxfpULVjUxL6EqNU77wbRmmhDBdKMVCEoLQdqaCQ11ywSwAjctw1KX6QegLSWtqWQdOcteH3y3vQt8SjNwTErG2qYpcCKWB0I62PCtNwP4HXdg-N2A8yueUjCiV1y2VScww0A7RqGSqbKmXStl1zVpoXXy-jhVG7tBSZFi8dDPTOcz1qz5yv3kpKpw2k4yeDMZeHc7qhD_seSJWkFalbHaJTORzknwc8oaXDNM20Qt_kKlR6YjFek-aZPGZ4J3M0FiovoVVzCGwJffvv4_e_1jzr49YtcK-rgOrh-jcTbMQXoAhXcheKUfksMF37fDfRp83w58aocke3Wc-oPo_v6TP46gCcM</recordid><startdate>20130122</startdate><enddate>20130122</enddate><creator>Yeka, Adoke</creator><creator>Tibenderana, James</creator><creator>Achan, Jane</creator><creator>D'Alessandro, Umberto</creator><creator>Talisuna, Ambrose O</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130122</creationdate><title>Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children</title><author>Yeka, Adoke ; Tibenderana, James ; Achan, Jane ; D'Alessandro, Umberto ; Talisuna, Ambrose O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antimalarials - adverse effects</topic><topic>Antimalarials - therapeutic use</topic><topic>Artemether</topic><topic>Artemisinin</topic><topic>Artemisinins - adverse effects</topic><topic>Artemisinins - therapeutic use</topic><topic>Biology</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Dihydroartemisinin</topic><topic>Disease transmission</topic><topic>Drug therapy</topic><topic>Effectiveness</topic><topic>Ethanolamines - adverse effects</topic><topic>Ethanolamines - therapeutic use</topic><topic>Fluorenes - adverse effects</topic><topic>Fluorenes - therapeutic use</topic><topic>Health risks</topic><topic>Humans</topic><topic>Infant</topic><topic>Infection</topic><topic>Infections</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Male</topic><topic>Medical law</topic><topic>Medicine</topic><topic>Patients</topic><topic>Plasmodium falciparum</topic><topic>Quinine</topic><topic>Quinine - adverse effects</topic><topic>Quinine - therapeutic use</topic><topic>Quinolines - adverse effects</topic><topic>Quinolines - therapeutic use</topic><topic>Recurrent infection</topic><topic>Safety</topic><topic>Statistical analysis</topic><topic>Surveillance</topic><topic>Therapy</topic><topic>Treatment Outcome</topic><topic>Uganda</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeka, Adoke</creatorcontrib><creatorcontrib>Tibenderana, James</creatorcontrib><creatorcontrib>Achan, Jane</creatorcontrib><creatorcontrib>D'Alessandro, Umberto</creatorcontrib><creatorcontrib>Talisuna, Ambrose O</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale_Opposing Viewpoints In Context</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeka, Adoke</au><au>Tibenderana, James</au><au>Achan, Jane</au><au>D'Alessandro, Umberto</au><au>Talisuna, Ambrose O</au><au>Gosling, Roly D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-01-22</date><risdate>2013</risdate><volume>8</volume><issue>1</issue><spage>e53772</spage><pages>e53772-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the two. Though several African countries continue to use quinine as the second line treatment for patients with recurrent infections, there is little information on its efficacy when used for rescue therapy. Moreover, such practice goes against the World Health Organisation (WHO) recommendation to use combination therapy for uncomplicated malaria. We conducted a nested, randomized, open label, three-arm clinical trial of rescue therapy in children 6-59 months old with recurrent malaria infection during 28 days post treatment with artemisinin combination treatment (ACT). Patients were randomly assigned to receive either quinine, artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHAPQ), and actively followed up for 28 days. Among 220 patients enrolled, 217 (98·6%) were assigned an efficacy outcome and 218 (99·1%) were assessed for safety. The risk of recurrent infection was significantly higher in patients treated with quinine (70%, 74/110, HR = 3·9; 95% CI: 2·4-6·7, p&lt;0·0001) and AL (60%, 21/35, HR = 3·3; 95% CI: 1·8-6·3, p&lt;0·0002), compared to DHAPQ (25%, 18/72). Recrudescence tended to be lower in the DHAPQ (1%, 1/72) than in the quinine (7%, 8/110) or AL (6%, 2/35) group, though it was not statistically significant. No serious adverse events were reported. Recurrent infections observed after the administration of an ACT can be successfully treated with an alternative ACT rather than with quinine. Current Controlled Trials ISRCTN99046537.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23349741</pmid><doi>10.1371/journal.pone.0053772</doi><tpages>e53772</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2013-01, Vol.8 (1), p.e53772
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1327798801
source Publicly Available Content Database; PubMed Central
subjects Antimalarials - adverse effects
Antimalarials - therapeutic use
Artemether
Artemisinin
Artemisinins - adverse effects
Artemisinins - therapeutic use
Biology
Child, Preschool
Children
Clinical trials
Dihydroartemisinin
Disease transmission
Drug therapy
Effectiveness
Ethanolamines - adverse effects
Ethanolamines - therapeutic use
Fluorenes - adverse effects
Fluorenes - therapeutic use
Health risks
Humans
Infant
Infection
Infections
Malaria
Malaria, Falciparum - drug therapy
Male
Medical law
Medicine
Patients
Plasmodium falciparum
Quinine
Quinine - adverse effects
Quinine - therapeutic use
Quinolines - adverse effects
Quinolines - therapeutic use
Recurrent infection
Safety
Statistical analysis
Surveillance
Therapy
Treatment Outcome
Uganda
Vector-borne diseases
title Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T11%3A57%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20quinine,%20artemether-lumefantrine%20and%20dihydroartemisinin-piperaquine%20as%20rescue%20treatment%20for%20uncomplicated%20malaria%20in%20Ugandan%20children&rft.jtitle=PloS%20one&rft.au=Yeka,%20Adoke&rft.date=2013-01-22&rft.volume=8&rft.issue=1&rft.spage=e53772&rft.pages=e53772-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0053772&rft_dat=%3Cgale_plos_%3EA478167149%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c758t-2a52f13861467f33c7f8feac440c3967cfa697ca7018971df27caaa92d464d7b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1327798801&rft_id=info:pmid/23349741&rft_galeid=A478167149&rfr_iscdi=true